Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ketamine for Depression in Cancer Patients
NCT02836288Phase 1Completed
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Ketamine with Placebo (2 arms). Primary endpoints: Proportion of patients pre-screened that were potentially eligible at 24 months, Proportion of approached patients that agreed to participate at 24 months and 1 more. Started Dec 2016; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02836288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836288.